Immunoinflammatory ocular diseases are common, sight-threatening inflammatory ocular diseases and include multiple clinical symptoms. The various types of classical immunoinflammatory ocular diseases contain allergic conjunctivitis, corneal ulcer, uveitis, optic neuritis, thyroid-related eye diseases, and so on. However, the pathogenesis of immunoinflammatory ocular diseases has remained unclear according to the mechanistic studies on animal or clinical samples. Research on mechanisms and treatments is necessary to understand the immunopathogenesis and therapy of this group of diseases.
Studies have shown that a key immune imbalance in autoimmune disease patients is the imbalance between regulatory T cells (Treg) and effector T cells (Teff). Restoring immune balance in immunoinflammatory ocular diseases has become one of the research highlights in ocular immunology. With the development of research techniques such as single-cell RNA-seq and metabonomics technology, the immunopathogenesis of these diseases has been revealed clearly. For example, aging reduced the pathogenicity of T helper 17 cells (Th17) by weakening GM-CSF/IL-23/IL-23R positive feedback loop.
This Research Topic seeks to highlight those new insights into the mechanism of immunoinflammatory ocular diseases. We focus on cutting-edge tools such as monoclonal antibody treatment, JAK inhibitors, and the application of advanced technologies to assess new targets in the development and progression of immunoinflammatory ocular diseases, such as single-cell RNA-seq, and metabonomics technology. This issue can then be used to offer evidence for new perspectives on the mechanism of immunoinflammatory ocular diseases and streamlining the route to clinical trials and standard use.
We welcome both basic and clinical research involving all aspects of immunoinflammatory ocular disease efforts. The submission of Original Research articles, Mini-Reviews, Reviews, Perspective articles, Opinions, and Case Reports are welcome here, on the following topics, but are not limited to:
• Possible pathogenesis of various immunoinflammatory ocular diseases and their associated immune changes
• Exploration and application of technologies such as single-cell sequencing and transcriptomics or any other new technologies in immunoinflammatory ocular diseases
• Potential therapeutic targets and drug research on immunoinflammatory ocular diseases
Immunoinflammatory ocular diseases are common, sight-threatening inflammatory ocular diseases and include multiple clinical symptoms. The various types of classical immunoinflammatory ocular diseases contain allergic conjunctivitis, corneal ulcer, uveitis, optic neuritis, thyroid-related eye diseases, and so on. However, the pathogenesis of immunoinflammatory ocular diseases has remained unclear according to the mechanistic studies on animal or clinical samples. Research on mechanisms and treatments is necessary to understand the immunopathogenesis and therapy of this group of diseases.
Studies have shown that a key immune imbalance in autoimmune disease patients is the imbalance between regulatory T cells (Treg) and effector T cells (Teff). Restoring immune balance in immunoinflammatory ocular diseases has become one of the research highlights in ocular immunology. With the development of research techniques such as single-cell RNA-seq and metabonomics technology, the immunopathogenesis of these diseases has been revealed clearly. For example, aging reduced the pathogenicity of T helper 17 cells (Th17) by weakening GM-CSF/IL-23/IL-23R positive feedback loop.
This Research Topic seeks to highlight those new insights into the mechanism of immunoinflammatory ocular diseases. We focus on cutting-edge tools such as monoclonal antibody treatment, JAK inhibitors, and the application of advanced technologies to assess new targets in the development and progression of immunoinflammatory ocular diseases, such as single-cell RNA-seq, and metabonomics technology. This issue can then be used to offer evidence for new perspectives on the mechanism of immunoinflammatory ocular diseases and streamlining the route to clinical trials and standard use.
We welcome both basic and clinical research involving all aspects of immunoinflammatory ocular disease efforts. The submission of Original Research articles, Mini-Reviews, Reviews, Perspective articles, Opinions, and Case Reports are welcome here, on the following topics, but are not limited to:
• Possible pathogenesis of various immunoinflammatory ocular diseases and their associated immune changes
• Exploration and application of technologies such as single-cell sequencing and transcriptomics or any other new technologies in immunoinflammatory ocular diseases
• Potential therapeutic targets and drug research on immunoinflammatory ocular diseases
